Skip to main content
Log in

Bioavailability of indomethacin from two multiple-units controlled-release formulations

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Two multiple-units controlled-release indomethacin capsule formulations containing enteric-coated pellets were bioequivalent to a standard capsule formulation (taken as the reference) in respect of extent of bioavailability in a crossover study with normal human subjects. However, drug absorption from the enteric-coated pellet formulations was slower, when compared to that from the standard reference capsule. The standard reference capsule released 85% of its drug content in vitro during 10 min at pH 6.5 and 98% during 1 h at pH 7.5. One enteric-coated pellet capsule formulation (I) released 77% during 1 h at pH 6.5 and the other (II) released 10% during 1 h at pH 6.5. Release of drug from each capsule of enteric-coated pellets was complete during 1 h at pH 7.5. Although differences in areas under the plasma indomethacin concentration-time curves were not significantly different, the peak plasma levels and the times of their occurrence indicated that the absorption rates of indomethacin decreased in the order, reference formulation > pellet formulation I > pellet formulation II, which was the same rank order as that of their dissolution rates in vitro. The data indicated that multiple units controlled-release formulations represent a reliable and reproducible source of indomethacin, which by avoiding extremes of local or systemic drug concentrations also should be better tolerated by individuals susceptible to unwanted gastrointestinal and centrally-mediated side-effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Goodman LS, Gilman A (1980) The pharmacological basis of therapeutics. McMillan, New York, p 706

    Google Scholar 

  2. Boardman PL, Hart FD (1967) Side-effects of indomethacin. Ann Rheum Dis 26: 127–132

    Google Scholar 

  3. Rothermich NO (1966) An extended study of indomethacin. J Am Med Assoc 195: 531–536

    Google Scholar 

  4. Alván G, Orme M, Bertilsson L, Ekstrand R, Palmér L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18: 364–373

    Google Scholar 

  5. Holt LPJ, Hawkins CF (1965) Indomethacin: studies of absorption and of the use of indomethacin suppositories. Br Med J 1: 1354–1356

    Google Scholar 

  6. Caruso I, Bianchi Porro G (1980) Gastroscopic evaluation of anti-inflammatory agents. Br Med J 1: 75–78

    Google Scholar 

  7. Donnelly P (1980) Indomethacin and perforated duodenal ulcer. Br Med J 2: 230

    Google Scholar 

  8. Bechgaard H, Hegermann Nielsen G (1978) Controlled Release multiple-units and single-unit doses. A literature review. Drug Dev Ind Pharm 4: 53–67

    Google Scholar 

  9. Blythe RH, Grass GM, McDonnel DR (1959) The formulation and evaluation of enteric coated aspirin tablets. Am J Pharm 131: 206–216

    Google Scholar 

  10. Wagner JG, Veldkamp W, Long S (1960) Enteric coatings IV. In vivo testing of granules and tablets coated with styrenemaleic acid copolymer. J Am Pharm Assoc Sci Ed 49: 128–132

    Google Scholar 

  11. Leonards JR, Levy G (1965) Absorption and metabolism of aspirin administered in enteric-coated tablets. J Am Med Assoc 193: 99–104

    Google Scholar 

  12. Wiik I, Sveen K, Renaa T, Dramsrud L (1975) In vitro dissolution and in vivo absorption of different acetylsalicylic acid tablets following single dose administration. Medd Nor Farm Selsk 37: 21–49

    Google Scholar 

  13. Bogentoft C, Carlsson I, Ekenved G, Magnusson A (1978) Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol 14: 351–355

    Google Scholar 

  14. Benet LZ (1973) In: Ariëns EJ (ed) Drug design, Vol 4. Academic Press, New York London, pp 1–35

    Google Scholar 

  15. Green DM (1966) Tablets of coated aspirin microspherules — A new dosage form. J New Drugs 6: 294–303

    Google Scholar 

  16. Green MA (1954) One years experience with sustained release anti-histamine medication. Ann Allergy 12: 273–283

    Google Scholar 

  17. Feinblatt TM, Gerguson EA (1956) Timed-disintegration capsules. An in vivo roentgenographic study. N Engl J Med 254: 940–943

    Google Scholar 

  18. Feinblatt TM, Ferguson EA (1957) Timed-disintegration capsules (Tymcaps) — A further study. An in vivo roentgenographic study, blood-level study and relief of anginal pain with pentaerythritol tetranitrate. N Engl J Med 256: 331–335

    Google Scholar 

  19. Casey DL, Beihn RM, Digenis GA, Shambhu MB (1976) Method for monitoring hard gelatine capsules disintegration times in humans using external scintigraphy. J Pharm Sci 65: 1412–1413

    Google Scholar 

  20. Bechgaard H, Ladefoged K (1978) Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J Pharm Pharmacol 30: 690–692

    Google Scholar 

  21. Bergdahl B, Bogentoft C, Jonsson UE, Magnusson JO (1980) Absorption of digoxin from a new microencapsulated formulation. Eur J Clin Pharmacol 17: 443–447

    Google Scholar 

  22. The national formulary XIV (1975) Mack Publishing Co., Easton, PA, p 985

  23. Snedecor GW, Cochran WG (1967) Statistical methods. Iowa State University Press, Iowa, pp 271–275

    Google Scholar 

  24. Cochran WG (1950) The comparison of percentages in matched samples. Biometrika 37: 256–266

    Google Scholar 

  25. Metzler C (1974) Bioavailability — a problem in equivalence. Biometrics 30: 309–317

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bechgaard, H., Brodie, R.R., Chasseaud, L.F. et al. Bioavailability of indomethacin from two multiple-units controlled-release formulations. Eur J Clin Pharmacol 21, 511–515 (1982). https://doi.org/10.1007/BF00542047

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542047

Key words

Navigation